公司資料
Blueprint Medicines 股價、新聞與催化劑
- 股票代碼:
- BPMC
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for BPMC.
公司概覽
業務概覽
Blueprint Medicines is a precision-oncology and rare-disease company with a strong focus on kinase biology and mast-cell disease.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Blueprint sits in targeted-therapy biotechnology.
商業模式特徵
Its model combines commercial product growth, targeted oncology development, and continued investment in rare-disease programs.
生技產業定位
Blueprint is a high-quality targeted-therapy biotech whose stock reacts to launches, data, and strategic optionality.
未來催化劑
- Blueprint Medicines's catalysts are Ayvakit in systemic mastocytosis and BLU-808 as the next immunology growth option. The market will care about whether the mast-cell franchise can keep expanding while the next program de-risks the pipeline.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。